PCI completes Penn Pharma purchase

Published: 4-Aug-2014 Featured companies: PCI Pharma Services
Manufacturing Packaging Regulatory Finance

Welcomes expanded services of Penn Pharma


Packaging Coordinators, Inc. (PCI) has finalised its agreement to acquire Penn Pharmaceutical Services Limited (Penn Pharma). Headquartered in Tredegar, Wales in the UK, Penn Pharma offers both drug development and manufacturing services, including clinical and commercial dosage form manufacturing, as well as clinical packaging, labelling, and global storage, distribution and return drug services.

PCI is headquartered in Philadelphia, Pennsylvania in the US. The combination of PCI and Penn Pharma features the expertise of approximately 2,800 associates across 15 facilities in North America and Europe. Across their supply network they manufacture and package both investigational and commercial medicines on behalf of their clients destined to more than 100 countries around the world.

PCI is principally owned by Frazier Healthcare, with partner investors QIC Global Private Equity, Greenspring Associates and Thomas, McNerney & Partners. Frazier Healthcare, founded in 1991 to invest exclusively in healthcare, is a leading provider of growth equity and venture capital to high growth and emerging healthcare companies.

Teneo Capital acted as the exclusive financial adviser to PCI and Frazier Healthcare for this transaction. PCI and Frazier Healthcare engaged global professional services firm Alvarez & Marsal to provide due diligence services. Goodwin Procter LLP acted as legal counsel to PCI and Frazier Healthcare for this transaction.

Featured companies

PCI Pharma Services: Your bridge between life-changing therapies and patients.
  • Companies:
  • Frazier Healthcare
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

CDMO insights: development and manufacture of a highly potent OSD product

Read more
In today’s pharmaceutical landscape, contract development and manufacturing organisations (CDMOs) are ubiquitous. Prior to the CDMO boom in the 1990s, however, this wasn’t the case

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  3. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    How CDMOs can set a new gold standard when it comes to going green Sustainability is more than a feel-good initiative or a choice; it’s a strategic imperative. Not missing a beat, pharma companies have been making a concerted effort towards positive change, reports Tim Lowery, President of JSR Life Sciences and CEO, KBI Biopharma
  5. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence

Relevant companies

See more

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

CDMO insights: development and manufacture of a highly potent OSD product

In today’s pharmaceutical landscape, contract development and manufacturing organisations (CDMOs) are ubiquitous. Prior to the CDMO boom in the 1990s, however, this wasn’t the case
Manufacturing

PCI Pharma Services invests $365m into its advanced injectable packaging capabilities

The company has expanded its final assembly and packaging capabilities for advanced injectable solutions in both Europe and the US
Manufacturing

PCI Pharma becomes first CDMO to complete an ICRMA site inspection

The ICMRA's pilot scheme aims to accelerate the regulatory approval process for pharmaceutical companies
Manufacturing

PCI Pharma Services at BIO Show: showcasing sterile fill-finish robotics for industry reference

The company will showcase its manufacturing capabilities both at Booth #6050 at BIO 2024, as well as at its San Diego facility
Manufacturing

PCI Pharma Services commences installation of sterile fill-finish and lyophilisation line

The Bedford, NH site will advance PCI's manufacturing capabilities with twin lyophilisers and a large-scale isolator filling line, making this the third sterile fill-finish facility built in the last three years
Manufacturing

Enhancing sterility: the crucial role of isolators in sterile fill-finish

Maintaining the highest levels of sterility is paramount to ensure the safety and efficacy of drugs, with good aseptic manufacturing practices playing a pivotal role in safeguarding patient health and well-being
Manufacturing

PCI Pharma Services releases inaugural ESG report

Highlights include environmental goals based on climate science, workforce empowerment, focus on local partnerships and supply chain resiliency
Subscribe now